Stemina Biomarker Discovery
Stemina Biomarker Discovery is dedicated to improving human health through innovative, cell-based assays that utilize human embryonic stem cells, induced pluripotent stem cells, and metabolomics. The company develops and commercializes molecular biomarkers and in vitro toxicity assays to enhance drug safety, reduce animal testing, and support regulatory acceptance. Its mission is to help organizations develop the safest compounds possible by providing predictive toxicology solutions, including assays for developmental and cardiotoxicity, and diagnostic tools for neurological disorders such as autism.
Industries
Nr. of Employees
small (1-50)
Stemina Biomarker Discovery
Madison, Wisconsin, United States, North America
Products
Biomarker-based developmental toxicity assay (service/product)
A screening assay that uses human pluripotent stem cells and metabolite biomarker ratios to indicate potential developmental toxicity and prioritize compounds.
Cardiotoxicity screening assay (metabolite-based)
An assay using iPSC-derived cardiomyocytes and a targeted metabolite panel to predict cardiotoxicity potential and classify known cardiotoxic and non-cardiotoxic compounds.
Blood-based metabolomics diagnostic assay for neurodevelopmental disorders
A clinical assay developed from cohort studies to detect metabolomic signatures associated with neurodevelopmental conditions for earlier diagnostic support.
Biomarker-based developmental toxicity assay (service/product)
A screening assay that uses human pluripotent stem cells and metabolite biomarker ratios to indicate potential developmental toxicity and prioritize compounds.
Cardiotoxicity screening assay (metabolite-based)
An assay using iPSC-derived cardiomyocytes and a targeted metabolite panel to predict cardiotoxicity potential and classify known cardiotoxic and non-cardiotoxic compounds.
Blood-based metabolomics diagnostic assay for neurodevelopmental disorders
A clinical assay developed from cohort studies to detect metabolomic signatures associated with neurodevelopmental conditions for earlier diagnostic support.
Services
In vitro developmental toxicity screening service
Laboratory service using human pluripotent stem cell assays and metabolite biomarkers to assess developmental toxicity potential of compounds.
In vitro cardiotoxicity screening service
Service utilizing iPSC-derived cardiomyocytes and targeted metabolite readouts to detect structural and functional cardiotoxicity signals.
Custom toxicology and biomarker services
Project-specific study design, execution, data analysis, and interpretation for toxicology screening and biomarker discovery.
Clinical diagnostic test development and translation
Translation of metabolomics-derived biomarker signatures from cohort studies into blood-based diagnostic assays for neurodevelopmental conditions.
In vitro developmental toxicity screening service
Laboratory service using human pluripotent stem cell assays and metabolite biomarkers to assess developmental toxicity potential of compounds.
In vitro cardiotoxicity screening service
Service utilizing iPSC-derived cardiomyocytes and targeted metabolite readouts to detect structural and functional cardiotoxicity signals.
Custom toxicology and biomarker services
Project-specific study design, execution, data analysis, and interpretation for toxicology screening and biomarker discovery.
Clinical diagnostic test development and translation
Translation of metabolomics-derived biomarker signatures from cohort studies into blood-based diagnostic assays for neurodevelopmental conditions.
Expertise Areas
- In vitro toxicology screening
- Developmental toxicology
- Cardiac safety assessment
- Metabolomics and biomarker discovery
Key Technologies
- Liquid chromatography–mass spectrometry (LC–MS)
- Targeted and non‑targeted metabolomics
- Human embryonic and induced pluripotent stem cells (hES/iPS)
- iPSC-derived cardiomyocytes